A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer.

Kari B Wisinski; Wendy M Ledesma; Jill Kolesar; George Wilding; Glenn Liu; Jeffrey Douglas; Anne M Traynor; Mark Albertini; Daniel Mulkerin; Howard H Bailey

首页> 外文期刊>Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners >A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer.

【24h】

A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer.

机译：一期研究旨在确定晚期癌症患者口服LR-103（1α，24（S）Dihydroxyvitamin D2）的最大耐受剂量和安全性。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Step A dose limiting toxicities limited accelerated dose escalation. The maximum tolerated dose of LR-103 was not reached prior to study termination and this agent is no longer being developed.

机译：步骤A剂量限制毒性限制了加速剂量增加。在研究终止之前未达到LR-103的最大耐受剂量，并且不再开发这种药物。

著录项

来源
《Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners》 |2015年第6期|共9页
作者
Kari B Wisinski; Wendy M Ledesma; Jill Kolesar; George Wilding; Glenn Liu; Jeffrey Douglas; Anne M Traynor; Mark Albertini; Daniel Mulkerin; Howard H Bailey;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献

1. A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. [J] . Kari B Wisinski, Wendy M Ledesma, Jill Kolesar, Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners . 2015,第6期

机译：一期研究旨在确定晚期癌症患者口服LR-103（1α，24（S）Dihydroxyvitamin D2）的最大耐受剂量和安全性。
2. A phase I study to determine the safety, tolerability and maximum tolerated dose of green-lipped mussel (Perna canaliculus)n lipid extract, in patients with advanced prostate and breast cancer [J] . T. J. Price Annals of Oncology . 2010,第5期

机译：一期研究，用于确定晚期前列腺癌和乳腺癌患者青唇贻贝（Perna canaliculus）n脂质提取物的安全性，耐受性和最大耐受剂量
3. Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer [J] . Mohammad H. Pourgholami, Michael Szwajcer, Melvin Chin, Cancer chemotherapy and pharmacology. . 2010,第3期

机译：一期临床试验以确定晚期癌症患者口服阿苯达唑的最大耐受剂量
4. Bioelectrical impedance phase angle as a predictor of survival in patients with advanced cancer. [C] . M. Marra, L. Santarpia, C. Montagnese, World congress on medical physics and biomedical engineering;International congress of the IUPESM . 2011

机译：生物电阻抗相角可作为晚期癌症患者生存的预测指标。
5. A robust paradigm of finding the maximum tolerated dose in Phase I cancer clinical trials with application to IL-21 denenicokin [D] . Young, Tina Chang. 2017

机译：在I期临床研究中将最大耐受剂量应用于IL-21 Denenicokin的最大范例
6. A Phase I Study to Determine the Maximum Tolerated Dose and Safety of Oral LR-103 (1α24(S)Dihydroxyvitamin D2) in Patients with Advanced Cancer [O] . Kari B Wisinski, Wendy M Ledesma, Jill Kolesar, -1

机译：一期研究确定晚期癌症患者口服LR-103（1α24（S）Dihydroxyvitamin D2）的最大耐受剂量和安全性
7. A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424 [O] . Woodcock, VK, Clive, S, Wilson, RH, 2018

机译：一项人类首次研究，旨在确定口服Src / ABL抑制剂AZD0424的最大耐受剂量
8. Results of a Maximum Tolerated Dose Study in Dogs and a 14-day Oral Dose Tolerability Study in Rats. [R] . 2011

机译：狗的最大耐受剂量研究结果和大鼠14天口服剂量耐受性研究。

A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer.

摘要

著录项

相似文献

相关主题

期刊订阅